Telaprevir Alone or With Peginterferon and Ribavirin Reduces HCV RNA in Patients With Chronic Genotype 2 but Not Genotype 3 Infections
- 1 September 2011
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 141 (3) , 881-889.e1
- https://doi.org/10.1053/j.gastro.2011.05.046
Abstract
No abstract availableKeywords
Funding Information
- Janssen Pharmaceuticals
This publication has 13 references indexed in Scilit:
- Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis CGastroenterology, 2011
- An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic ResponseGastroenterology, 2010
- The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virusExpert Opinion on Investigational Drugs, 2009
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV InfectionNew England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis CGastroenterology, 2008
- Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis CHepatology, 2007
- [12] TELAPREVIR (VX-950) IS A POTENT INHIBITOR OF HCV NS3 PROTEASES DERIVED FROM GENOTYPE NON-1 HCV-INFECTED PATIENTSJournal of Hepatology, 2007
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004